74 related articles for article (PubMed ID: 36005562)
1. Twist family BHLH transcription factor 1 is required for the maintenance of leukemia stem cell in MLL-AF9
Wang N; Yin J; You N; Zhu W; Guo N; Liu X; Zhang P; Huang W; Xie Y; Ren Q; Ma X
Haematologica; 2024 Jan; 109(1):84-97. PubMed ID: 37767575
[TBL] [Abstract][Full Text] [Related]
2. SET-PP2A complex as a new therapeutic target in KMT2A (MLL) rearranged AML.
Di Mambro A; Arroyo-Berdugo Y; Fioretti T; Randles M; Cozzuto L; Rajeeve V; Cevenini A; Austin MJ; Esposito G; Ponomarenko J; Lucas CM; Cutillas P; Gribben J; Williams O; Calle Y; Patel B; Esposito MT
Oncogene; 2023 Dec; 42(50):3670-3683. PubMed ID: 37891368
[TBL] [Abstract][Full Text] [Related]
3. The epigenetic regulators EP300/CREBBP represent promising therapeutic targets in MLL-rearranged acute myeloid leukemia.
Wu W; Jiang Y; Xing D; Zhai Y; Sun H; He X; Luo K; Xu P; Pan F; Dong G; Ren G; Zhao Z
Cell Death Discov; 2024 May; 10(1):206. PubMed ID: 38693103
[TBL] [Abstract][Full Text] [Related]
4. The Biology and Targeting of FLT3 in Pediatric Leukemia.
Annesley CE; Brown P
Front Oncol; 2014; 4():263. PubMed ID: 25295230
[TBL] [Abstract][Full Text] [Related]
5. Discovery of novel pyrrolo[2,3-d]pyrimidines as potent menin-mixed lineage leukemia interaction inhibitors.
Bai H; Yang Z; Lei H; Wu Y; Liu J; Yuan B; Ma M; Gao L; Zhang SQ; Xin M
Eur J Med Chem; 2024 Mar; 268():116226. PubMed ID: 38367493
[TBL] [Abstract][Full Text] [Related]
6. Systematic characterization of the HOXA9 downstream targets in MLL-r leukemia by noncoding CRISPR screens.
Wright S; Zhao X; Rosikiewicz W; Mryncza S; Hyle J; Qi W; Liu Z; Yi S; Cheng Y; Xu B; Li C
Nat Commun; 2023 Nov; 14(1):7464. PubMed ID: 38016946
[TBL] [Abstract][Full Text] [Related]
7. A Fibrinogen Alpha Fragment Mitigates Chemotherapy-Induced
Eberle J; Wiehe RS; Gole B; Mattis LJ; Palmer A; Ständker L; Forssmann WG; Münch J; Gebhardt JCM; Wiesmüller L
Front Oncol; 2021; 11():689063. PubMed ID: 34222016
[TBL] [Abstract][Full Text] [Related]
8. CMSS1::FLT1 rearrangement leads to ligand-independent activation of FLT1 signaling in acute myeloid leukemia.
Zhang L; Yang X; Ge X; Li B; Zhang H; Li J; Liu L; Chen X; Hu W; Sun Y; Xiao S
Am J Hematol; 2023 Dec; 98(12):E380-E382. PubMed ID: 37792599
[No Abstract] [Full Text] [Related]
9. SCUBE Diving: Biomarker Discovery for Pulmonary Hypertension From Bench to Bedside.
Gomez-Arroyo J; Voelkel NF; Abbate A
JACC Basic Transl Sci; 2020 Nov; 5(11):1093-1094. PubMed ID: 33296445
[TBL] [Abstract][Full Text] [Related]
10. The biology of SCUBE.
Lin YC; Sahoo BK; Gau SS; Yang RB
J Biomed Sci; 2023 May; 30(1):33. PubMed ID: 37237303
[TBL] [Abstract][Full Text] [Related]
11. HOXA9/MEIS1 targets in leukemia: reinforced signaling networks and therapeutic opportunities.
Zhou X; Lu R
Haematologica; 2023 May; 108(5):1205-1207. PubMed ID: 36005566
[No Abstract] [Full Text] [Related]
12. Synergistic targeting of FLT3 mutations in AML via combined menin-MLL and FLT3 inhibition.
Dzama MM; Steiner M; Rausch J; Sasca D; Schönfeld J; Kunz K; Taubert MC; McGeehan GM; Chen CW; Mupo A; Hähnel P; Theobald M; Kindler T; Koche RP; Vassiliou GS; Armstrong SA; Kühn MWM
Blood; 2020 Nov; 136(21):2442-2456. PubMed ID: 32589720
[TBL] [Abstract][Full Text] [Related]
13. MLL-AF9 and FLT3 cooperation in acute myelogenous leukemia: development of a model for rapid therapeutic assessment.
Stubbs MC; Kim YM; Krivtsov AV; Wright RD; Feng Z; Agarwal J; Kung AL; Armstrong SA
Leukemia; 2008 Jan; 22(1):66-77. PubMed ID: 17851551
[TBL] [Abstract][Full Text] [Related]
14. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.
Li Z; Chen P; Su R; Hu C; Li Y; Elkahloun AG; Zuo Z; Gurbuxani S; Arnovitz S; Weng H; Wang Y; Li S; Huang H; Neilly MB; Wang GG; Jiang X; Liu PP; Jin J; Chen J
Cancer Res; 2016 Feb; 76(3):619-29. PubMed ID: 26747896
[TBL] [Abstract][Full Text] [Related]
15. Expression of FLT3 receptor and response to FLT3 ligand by leukemic cells.
Drexler HG
Leukemia; 1996 Apr; 10(4):588-99. PubMed ID: 8618433
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges.
Sternberg DW; Licht JD
Curr Opin Hematol; 2005 Jan; 12(1):7-13. PubMed ID: 15604885
[TBL] [Abstract][Full Text] [Related]
17. Signal peptide-CUB-EGF-like repeat-containing protein 1-promoted FLT3 signaling is critical for the initiation and maintenance of MLL-rearranged acute leukemia.
Sahoo BK; Lin YC; Tu CF; Lin CC; Liao WJ; Li FA; Li LH; Mou KY; Roffler SR; Wang SP; Yeh CT; Yao CY; Hou HA; Chou WC; Tien HF; Yang RB
Haematologica; 2023 May; 108(5):1284-1299. PubMed ID: 36005562
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
